Mergers, tender offers, buyouts and asset sales involving Japanese companies, in English.
Kurabo Industries will buy 21.6mn TAUNS Laboratories shares from Trustar funds and TAUNS's president, taking 20.27% of voting rights with a director nomination right and consent rights, while Trustar keeps 23.85% by TAUNS's estimate.
Tillotts, Zeria's Swiss subsidiary, has signed to buy all of Haupt Pharma Wülfling, the German site that makes most of its Asacol, from Aenova; the price is undisclosed and closing is planned for January 2027 or later, subject to approvals.
Daito, Meiji Seika Pharma and the Development Bank of Japan plan a joint company to take over Kyorin Pharmaceutical's generic business, with the absorption split set for March 31, 2027 and closing on April 1.
Shionogi will buy all of US rare-disease drugmaker IntraBio for $2bn, taking worldwide rights to AQNEURSA, which won a first-of-its-kind ataxia-telangiectasia approval on 18 September; closing is targeted for November or December, subject to clearances.
Daito Pharmaceutical is folding into a new joint venture to absorb Kyorin's generic drug business while telling lawmakers that three straight years of annual price cuts have made its dominant Parkinson's disease tablet impossible to produce at a profit.
The move: Towa plans to buy Tanabe Pharma Factory outright, start transferring 35 manufacturing and marketing approvals from April 2027 onward and use the added capacity to target 24bn tablets by 2030 and more than 30bn by 2036.
GNI plans to buy all of Ayumi Pharmaceutical Holdings for ¥44.776 billion and make it a wholly owned unit, arguing the deal adds a steadier Japanese earnings base plus an established sales network in rheumatology, orthopedics and fever-and-pain drugs. Ayumi reported revenue of ¥38.543 billion and operating profit of ¥6.206 billion in the year to March 2026, giving GNI a domestic commercial platform rather than just another pipeline promise. The financing is the real tell. GNI will pay ¥18.005 billion in cash and settle ¥26.771 billion through a contribution in kind, issuing 9,974,291 new shares to the sellers, while also lining up ¥20 billion of borrowing from Mizuho Bank and SBI Shinsei Bank. Management says the deal should close between June 30 and September 30, but existing holders face 17.89% share dilution and BCP is expected to emerge as the largest shareholder.